Cargando…

The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking

BACKGROUND: Interstitial lung disease (ILD) is associated with substantial morbidity and mortality, which is one of the key systematic manifestations of connective tissue disease (CTD). Tripterygium wilfordii, known as Leigongteng in Chinese, has been applied to treat connective tissue disease-relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Wen, Li, Yehui, Zhao, Junjie, Wang, Yifan, Li, Yixi, Wang, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843192/
https://www.ncbi.nlm.nih.gov/pubmed/35132912
http://dx.doi.org/10.1080/07853890.2022.2034931
_version_ 1784651202321973248
author Zhu, Wen
Li, Yehui
Zhao, Junjie
Wang, Yifan
Li, Yixi
Wang, Yue
author_facet Zhu, Wen
Li, Yehui
Zhao, Junjie
Wang, Yifan
Li, Yixi
Wang, Yue
author_sort Zhu, Wen
collection PubMed
description BACKGROUND: Interstitial lung disease (ILD) is associated with substantial morbidity and mortality, which is one of the key systematic manifestations of connective tissue disease (CTD). Tripterygium wilfordii, known as Leigongteng in Chinese, has been applied to treat connective tissue disease-related interstitial lung disease (CTD-ILD) for many years. Triptolide is a key effective component from Tripterygium wilfordii. But the molecular mechanism of Triptolide for treating CTD-ILD is not yet clear. METHODS: Gaining insight into the molecular mechanism of Triptolide intervention CTD-ILD, we used the method of network pharmacology. And then we conducted drug-target networks to analyse the potential protein targets between Triptolide and CTD-ILD. Finally, AutoDock Vina was selected for molecular docking. RESULTS: By analysing the interaction genes between Triptolide and CTD-ILD, 242 genes were obtained. The top 10 targets of the highest enrichment scores were STAT3, AKT1, MAPK1, IL6, TP53, MAPK3, RELA, TNF, JUN, JAK2. GO and KEGG enrichment analysis exhibited that multiple signalling pathways were involved. PI3K-Akt, multiple virus infections, cancer signalling, chemokine, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. And it is related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. Molecular docking shows Triptolide can bind with its target protein in a good bond by intermolecular force. CONCLUSIONS: This study preliminarily reveals the internal molecular mechanism of Triptolide interfere with CTD-ILD through multiple targets, multiple access, validated through molecular docking. KEY MESSAGES: Triptolide intervention CTD-ILD, which are related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. PI3K-Akt, multiple virus infections, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. Triptolide can bind with related target protein in a good bond by Intermolecular force, exhibiting a good docking activity.
format Online
Article
Text
id pubmed-8843192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-88431922022-02-15 The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking Zhu, Wen Li, Yehui Zhao, Junjie Wang, Yifan Li, Yixi Wang, Yue Ann Med Pulmonary Medicine BACKGROUND: Interstitial lung disease (ILD) is associated with substantial morbidity and mortality, which is one of the key systematic manifestations of connective tissue disease (CTD). Tripterygium wilfordii, known as Leigongteng in Chinese, has been applied to treat connective tissue disease-related interstitial lung disease (CTD-ILD) for many years. Triptolide is a key effective component from Tripterygium wilfordii. But the molecular mechanism of Triptolide for treating CTD-ILD is not yet clear. METHODS: Gaining insight into the molecular mechanism of Triptolide intervention CTD-ILD, we used the method of network pharmacology. And then we conducted drug-target networks to analyse the potential protein targets between Triptolide and CTD-ILD. Finally, AutoDock Vina was selected for molecular docking. RESULTS: By analysing the interaction genes between Triptolide and CTD-ILD, 242 genes were obtained. The top 10 targets of the highest enrichment scores were STAT3, AKT1, MAPK1, IL6, TP53, MAPK3, RELA, TNF, JUN, JAK2. GO and KEGG enrichment analysis exhibited that multiple signalling pathways were involved. PI3K-Akt, multiple virus infections, cancer signalling, chemokine, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. And it is related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. Molecular docking shows Triptolide can bind with its target protein in a good bond by intermolecular force. CONCLUSIONS: This study preliminarily reveals the internal molecular mechanism of Triptolide interfere with CTD-ILD through multiple targets, multiple access, validated through molecular docking. KEY MESSAGES: Triptolide intervention CTD-ILD, which are related to various biological processes such as inflammation, infection, cell apoptosis, and cancer. PI3K-Akt, multiple virus infections, and apoptosis signalling pathway are the main pathways for Triptolide intervention CTD-ILD. Triptolide can bind with related target protein in a good bond by Intermolecular force, exhibiting a good docking activity. Taylor & Francis 2022-02-08 /pmc/articles/PMC8843192/ /pubmed/35132912 http://dx.doi.org/10.1080/07853890.2022.2034931 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Pulmonary Medicine
Zhu, Wen
Li, Yehui
Zhao, Junjie
Wang, Yifan
Li, Yixi
Wang, Yue
The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
title The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
title_full The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
title_fullStr The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
title_full_unstemmed The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
title_short The mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
title_sort mechanism of triptolide in the treatment of connective tissue disease-related interstitial lung disease based on network pharmacology and molecular docking
topic Pulmonary Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843192/
https://www.ncbi.nlm.nih.gov/pubmed/35132912
http://dx.doi.org/10.1080/07853890.2022.2034931
work_keys_str_mv AT zhuwen themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT liyehui themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT zhaojunjie themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT wangyifan themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT liyixi themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT wangyue themechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT zhuwen mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT liyehui mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT zhaojunjie mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT wangyifan mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT liyixi mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking
AT wangyue mechanismoftriptolideinthetreatmentofconnectivetissuediseaserelatedinterstitiallungdiseasebasedonnetworkpharmacologyandmoleculardocking